Expert Opinion on Biological Therapy 15.6 (2015): 873-81
ISSN:1471-2598; 1744-7682 (on line)
DOI:10.1517/14712598.2015.1040386
Funded by:This project is supported by research grants PS12/01754 (Spanish Ministry of Science) and
INVICTUS (RD12/0014/0006) (Spanish Neurovascular Network), and Research Institute Carlos
III, Ministry Science and Innovation
Introduction: Based on the positive results observed in experimental animal models, adipose
tissue-derived mesenchymal stem cells (AD-MSCs) constitute a promising therapy for stroke
treatment. However, several aspects need to be clarified to identify the optimal conditions for
successful clinical translation.
Areas covered: This review focuses on AD-MSC treatment for ischemic and hemorrhagic stroke
in experimental animal models. In addition, we will explore the optimization of treatment
conditions including AD-MSC production, administration routes and therapeutic windows for
their appropriate use in patients, and we will provide an update on clinical trials on this
therapy.
Expert opinion: Compared with other cell types, AD-MSCs have been less investigated in
stroke studies. Currently, experimental animal models have shown safety and efficacy with this
treatment after stroke. Due to several advantages of AD-MSCs, such as their abundance and
accessibility, they can be considered a promising strategy for use in patients. However, many
questions are still to be resolved regarding their mechanisms of action, immune system
modulation and the effects of AD-MSCs on all components of the brain that may be affected
after ischemic and hemorrhagic strokes